Lin Cheng-Wei
Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan City, Taiwan.
Clin Med Insights Arthritis Musculoskelet Disord. 2022 Mar 23;15:11795441221081061. doi: 10.1177/11795441221081061. eCollection 2022.
Under the ongoing COVID-19 pandemic, vaccines have become the crucial players to reduce the spread of the infection. Among them, the ChAdOx1 nCoV-19 vaccine is an adenoviral vector vaccine with an overall efficacy of 70.4% in protection. The engineered adenovirus contains the SARS-CoV-2 spike protein gene and pushes its DNA into the vaccinated cell's nucleus and subsequently, the spike protein can be made. During vaccination, the genome transition of adenovirus is influenced by the architecture and dynamics of the microtubule. Colchicine can alter microtubule dynamics by suppressing microtubule dynamics at lower concentrations and inducing depolymerization of microtubules at higher concentrations. Accordingly, the delivery of the genome to the vaccinated cell's nucleus by the adenoviral vector could be hindered under the presence of colchicine. Nevertheless, colchicine is a common medication for gout therapy worldwide, and though not recommended by guidelines, colchicine has even been taken into consideration as a possible therapeutic option for COVID-19 infection. Given the above reasons and the worldwide use of colchicine, the impact of colchicine on the efficacy of the COVID-19 vaccine via adenoviral vector should be viewed cautiously.
在当前的新冠疫情大流行期间,疫苗已成为减少感染传播的关键因素。其中,ChAdOx1 nCoV-19疫苗是一种腺病毒载体疫苗,总体保护效力为70.4%。这种经过改造的腺病毒包含严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白基因,并将其DNA推入接种疫苗的细胞细胞核,随后可产生刺突蛋白。在接种疫苗过程中,腺病毒的基因组转变受微管的结构和动力学影响。秋水仙碱可通过在较低浓度下抑制微管动力学以及在较高浓度下诱导微管解聚来改变微管动力学。因此,在秋水仙碱存在的情况下,腺病毒载体将基因组递送至接种疫苗细胞细胞核的过程可能会受到阻碍。尽管如此,秋水仙碱是全球治疗痛风的常用药物,并且尽管未被指南推荐,但秋水仙碱甚至已被考虑作为新冠病毒感染的一种可能治疗选择。鉴于上述原因以及秋水仙碱在全球的使用情况,应谨慎看待秋水仙碱对腺病毒载体新冠疫苗效力的影响。